Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96. Following the sale, the chief executive officer owned 705,995 shares of the company’s stock, valued at approximately $20,205,576.90. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Price Performance

CUE traded up $3.12 during midday trading on Friday, reaching $34.20. 157,074 shares of the company’s stock traded hands, compared to its average volume of 195,652. The stock has a market capitalization of $143.64 million, a price-to-earnings ratio of -6.12 and a beta of 2.47. The firm has a fifty day moving average of $29.50 and a two-hundred day moving average of $147.28. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The company had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen raised Cue Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Cue Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Cue Biopharma in the 2nd quarter worth approximately $83,000. Persistent Asset Partners Ltd bought a new stake in Cue Biopharma in the second quarter worth $389,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cue Biopharma in the second quarter worth $722,000. ADAR1 Capital Management LLC purchased a new stake in shares of Cue Biopharma in the second quarter worth $1,742,000. Finally, BlackRock Inc. bought a new position in shares of Cue Biopharma during the second quarter valued at $1,824,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.